Details

Autor(en) / Beteiligte

• Bayan, Claire-Audrey Y.
• Lopez, Adriana T.
• Gartrell, Robyn D.
• Komatsubara, Kimberly M.
• Bogardus, Margaret
• Rao, Nisha
• Chen, Cynthia
• Hart, Thomas D.
• Enzler, Thomas
• Rizk, Emanuelle M.
• Pradhan, Jaya Sarin
• Marks, Douglas K.
• Geskin, Larisa J.
• Saenger, Yvonne M.

Titel

The Role of Oncolytic Viruses in the Treatment of Melanoma

Ist Teil von

• Current oncology reports, 2018-10, Vol.20 (10), p.80-14, Article 80

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2018

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Purpose of Review Oncolytic virotherapy is a new approach to the treatment of cancer and its success in the treatment of melanoma represents a breakthrough in cancer therapeutics. This paper provides a review of the current literature on the use of oncolytic viruses (OVs) in the treatment of melanoma. Recent Findings Talimogene laherparepvec (T-VEC) is the first OV approved for the treatment of melanoma and presents new challenges as it enters the clinical setting. Several other OVs are at various stages of clinical and pre-clinical development for the treatment of melanoma. Reports from phase Ib-III clinical trials combining T-VEC with checkpoint blockade are encouraging and demonstrate potential added benefit of combination immunotherapy. Summary OVs have recently emerged as a standard treatment option for patients with advanced melanoma. Several OVs and therapeutic combinations are in development. Immunooncolytic virotherapy combined with immune checkpoint inhibitors is promising for the treatment of advanced melanoma.